Short answer
IQVIA (IQV) filed its Q3 2025 10-Q quarterly report on Oct 28, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $4.1B (up 5.2% year over year) with net income of $331M.
Q3 2025 key financials · XBRL
- Revenue
- $4.1B
- +5.2% YoY · +2.1% QoQ
- Net income
- $331M
- +16.1% YoY · +24.4% QoQ
- Operating margin
- 13.5%
- EPS (diluted)
- $1.92
- +23.9% YoY · +24.7% QoQ
Source: XBRL data from the IQVIA (IQV) Q3 2025 10-Q on SEC EDGAR. USD.
IQVIA Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $4,100M Q3 2025, up 5.2% YoY ($204M increase); Technology & Analytics +$52M, R&D +$73M, Contract Sales +$25M
- Operating margin decreased: Segment profit $1,555M YTD, down 1.3% YoY ($21M); Technology & Analytics profit +1.6%, R&D profit -4.3%, Contract Sales profit +5.9%
- Best performing segment revenue growth: Contract Sales & Medical Solutions +16.1% Q3; Worst segment profit decline: Research & Development Solutions -0.4% Q3, -4.3% YTD
- Cash balance increased to $1,814M Sep 30, 2025 from $1,702M; Operating cash flow $1,919M YTD, up $88M YoY; repurchased 6.4M shares for $1,032M in 9 months
- Management expects sufficient liquidity for next 12 months; noted ongoing restructuring to reduce overcapacity; new $2B senior notes issued in June 2025; monitors tax changes and foreign currency impacts
Risk Factors
- No new or changed risk factors since 2024 Form 10-K
- Continued exposure to regulatory risks in global healthcare compliance
- Market risks persist from competitive pressures in contract research services
- Financial risk from debt maturity management as detailed in 2024 Form 10-K
- Liquidity risks and currency exposure remain key considerations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other IQVIA quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.